From a retrospective study of 205 patients with advanced NSCLC from Johns Hopkins Hospital who were treated with anti-PD-1/PD-L1 between 2007 and 2017, the median onset time of CIP was 82 days (Suresh et al., 2018). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.